Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Expanded Controlled Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-Blind, Parallel-Group, Placebo-Controlled Manner (Phase 3)

Next Previous
Trial Profile

An Expanded Controlled Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-Blind, Parallel-Group, Placebo-Controlled Manner (Phase 3)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edaravone (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation

    • Most Recent Events

    • 01 Nov 2022 Results of post hoc analysis from MCI186-16, MCI186-17, and MCI186-19 examining the relationship between urate levels at baseline and functional change measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised total score after edaravone treatment,published in the Muscle and Nerve
    • 01 Nov 2022 Results of Post hoc analysis of studies( MCI186-16, MCI186-17, and MCI186-19)Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment published in the Muscle and Nerve
    • 30 Aug 2016 According to a Mitsubishi Tanabe Pharma media release, the US FDA accepted the NDA for edaravone (MCI-186), an intravenous treatment for ALS. The decision on the NDA expected in June 2017 based on the PDUFA.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top